REG - AstraZeneca PLC - Block listing Interim Review

AstraZenecaAnnouncement

01/12/2020 15:00

RNS Number : 1532H
  
AstraZeneca PLC
  
01 December 2020
  
 

1 December 2020 15:00 GMT
 
 
BLOCK LISTING SIX MONTHLY RETURN
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
(Note: Italicised terms have the same meaning as given in the Listing Rules.)
 
Date: 1 December 2020 
 



Name of applicant:


ASTRAZENECA PLC




Name of scheme:


ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME




Period of return:


From:


1 JUNE 2020


To:


30 NOVEMBER 2020




Balance of unallotted securities under scheme(s) from previous return:


763,535




Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


0




Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


54,083




Equals:  Balance under scheme(s) not yet issued/allotted at end of period:


709,452










 



Name of contact:


HANNAH TATTERSALL




Telephone number of contact:


+44 (0)746 498 2582



 
 
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BLRFSAFLFESSEDE